Suzhou Pharmavan Cancer Research Center

Pharmavan is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. The company primarily focuses on the DNA damage response (DDR) pathway, utilizing synthetic lethality principles to target cancer cells. Its lead clinical candidate, PV-001, is a potent and selective PARP inhibitor currently being evaluated in Phase 1/2 trials for various advanced solid tumors. Pharmavan leverages its internal R&D center, often referred to as the Suzhou Pharmavan Cancer Research Center, to advance a pipeline of targeted therapies designed to address significant unmet needs in cancer care.